<DOC>
	<DOCNO>NCT02675491</DOCNO>
	<brief_summary>This Phase 1 study evaluate safety , tolerability , pharmacokinetics DS-6051b Japanese subject advance solid malignant tumor harbor either ROS1 NTRK fusion gene .</brief_summary>
	<brief_title>Phase 1 Study DS-6051b Japanese Subjects With Advanced Solid Malignant Tumors</brief_title>
	<detailed_description>This study single arm study DS-6051b approximately 9 subject advance solid malignant tumor harbor either ROS1 NTRK fusion gene . Safety tolerability , pharmacokinetics ( PK ) , MTD/RP2D ( maximum tolerate dose/recommended phase 2 dose ) preliminary efficacy DS-6051b evaluate .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Advanced solid malignant tumor refractory standard therapy standard therapy available . An Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 . Previously currently follow disease : Cardiac failure ( NYHA Functional Classification â‰¥ Class III ) , myocardial infarction , cerebral infarction , unstable angina , arrhythmia require treatment , coronary/peripheral artery disease , pulmonary thrombosis , uncontrolled deep vein thrombosis , clinically severe thromboembolic event , autoimmune disease require treatment . Previously currently clinically severe pulmonary disease ( eg , interstitial pneumonia , pneumonitis , pulmonary fibrosis , radiation pneumonia ) . Severe uncontrolled concomitant disease . Clinically active brain metastasis central nervous system tumor require steroid anticonvulsant treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>DS-6051b</keyword>
	<keyword>ROS1</keyword>
	<keyword>NTRK</keyword>
	<keyword>refractory standard therapy</keyword>
	<keyword>standard therapy</keyword>
</DOC>